ProQR Therapeutics (PRQR) Non-Current Deffered Revenue (2015 - 2025)

ProQR Therapeutics' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $24.9 million for Q4 2025.

• In Q4 2025, Non-Current Deffered Revenue fell 20.81% year-over-year to $24.9 million; the TTM figure through Dec 2025 stood at $24.9 million (down 20.81% YoY), while the FY2025 annual figure was $24.9 million, down 20.81% from the prior year.
• Non-Current Deffered Revenue came in at $24.9 million for Q4 2025 at ProQR Therapeutics, down from $31.4 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $69.6 million in Q1 2023 to a low of $687.55 in Q1 2021.
• A 5-year average of $31.4 million and a median of $24.2 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue plunged 99.89% in 2021 and soared 2211913.24% in 2022, its largest moves.
• ProQR Therapeutics' Non-Current Deffered Revenue stood at $16.8 million in 2021, then soared by 298.15% to $66.9 million in 2022, then slipped by 28.96% to $47.5 million in 2023, then slumped by 33.83% to $31.4 million in 2024, then dropped by 20.81% to $24.9 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $24.9 million, $31.4 million, and $47.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison